ClinicalTrials.gg
CompletedNCT04720885Updated May 11, 2023

Management of Large Retained Products of Conception (> 4 cm): Need for an Standardized Procedure.

An observational study in Placenta, Retained, Placenta; Retention, Fragments, Complicating Puerperium, Without Hemorrhage and Placenta; Retention, Fragments, Complicating Puerperium (Delayed Hemorrhage), sponsored by University Hospital, Ghent. Completed at 1 site in Belgium. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-11.

Sponsored by University Hospital, Ghent · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
27
Ages
18 Years to 50 Years
Sex
Female
01

Study summary

Collection of relevant data form patients who were treated in the Ghent University Hospital in the context of a placental remnant lager than 4 cm, performing statistical analyzes on the collected data, reviewing the literature on the subject and formulation of a recommendation for treatment of these large placental remnants.

02

Conditions studied

  • Placenta, Retained
  • Placenta; Retention, Fragments, Complicating Puerperium, Without Hemorrhage
  • Placenta; Retention, Fragments, Complicating Puerperium (Delayed Hemorrhage)
  • Pregnancy Related
  • Hysteroscopy / Methods
  • Retrospective Studies
  • Vacuum Curettage
03

In context

Lead sponsor

University Hospital, Ghent is the lead sponsor of 685 studies on the registry; 158 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients with a placental remnant in medical history.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • retained products of conception larger than 4 cm in largest dimension

Exclusion criteria

Exclusion Criteria:

  • retained products of conception 4 cm or smaller in largest dimension
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
27 participants (actual)
Patient registry
No

Groups and cohorts

  • Patients with a placental remnant in medical history

    Procedure: kind of surgery

Interventions

  • Procedurekind of surgery

    hysteroscopy, curettage, other

06

What researchers measure

Primary outcomes

  1. Hysteroscopy

    Kind of surgery to remove retained products of conception

    Time frame: time of surgery

  2. Vacuum Curettage

    Kind of surgery to remove retained products of conception

    Time frame: time of curettage

  3. Polyp forceps

    Surgical instrument to remove retained products of conception

    Time frame: time of surgery

  4. Prostaglandines

    Pharmacological agent to remove retained products of conception

    Time frame: time of surgery

07

Study locations

1 site
  • Ghent University Hospital
    Ghent, 9000, Belgium
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2020 to primary completion in Aug 2021, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2021
First posted
Jan 22, 2021
StartActual
Dec 28, 2020
Primary completionActual
Aug 31, 2021
CompletionActual
Aug 31, 2021
Last update
May 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04720885
Responsible party
Sponsor
First posted
Jan 22, 2021
Start date
Dec 28, 2020
Primary completion
Aug 31, 2021
Completion
Aug 31, 2021
Last update
May 11, 2023

Study contacts

Tjalina Hamerlynck, MD
principal investigator · University Hospital, Ghent

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion